Tuyen Ong, M.D., M.B.A.

Dr. Tuyen Ong is currently the Chief Executive Officer at Ring Therapeutics and a CEO-Partner at Flagship Pioneering. Prior to Ring, Dr. Ong was Senior Vice President, Head of the Ophthalmology Franchise at Biogen and was Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen in 2019. Additionally, while at Nightstar, Dr. Ong was involved with the company’s NASDAQ IPO. Previously, Dr. Ong served as Chief Medical Officer at PTC Therapeutics and was responsible for progressing its pipeline of therapies for rare and genetic diseases. He also held leadership roles at Bausch and Lomb and at Pfizer, with more than 20 years’ experience in clinical and drug development. Dr. Ong was awarded his M.D. from University College London and his M.B.A. from New York University Stern School of Business.